Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Cancer Res. 2022 Oct 17;82(20):3774-3784. doi: 10.1158/0008-5472.CAN-22-0970.
T-cell immunoglobulin mucin family member 3 (Tim-3) is an immune checkpoint receptor that dampens effector functions and causes terminal exhaustion of cytotoxic T cells. Tim-3 inhibitors are under investigation in immuno-oncology (IO) trials, because blockade of T-cell-Tim-3 enhances antitumor immunity. Here, we identify an additional role for Tim-3 as a growth-suppressive receptor intrinsic to melanoma cells. Inhibition of melanoma cell-Tim-3 promoted tumor growth in both immunocompetent and immunocompromised mice, while melanoma-specific Tim-3 overexpression attenuated tumorigenesis. Ab-mediated Tim-3 blockade inhibited growth of immunogenic murine melanomas in T-cell-competent hosts, consistent with established antitumor effects of T-cell-Tim-3 inhibition. In contrast, Tim-3 Ab administration stimulated tumorigenesis of both highly and lesser immunogenic murine and human melanomas in T-cell-deficient mice, confirming growth-promoting effects of melanoma-Tim-3 antagonism. Melanoma-Tim-3 activation suppressed, while its blockade enhanced, phosphorylation of pro-proliferative downstream MAPK signaling mediators. Finally, pharmacologic MAPK inhibition reversed unwanted Tim-3 Ab-mediated tumorigenesis in T-cell-deficient mice and enhanced desired antitumor activity of Tim-3 interference in T-cell-competent hosts. These results identify melanoma-Tim-3 blockade as a mechanism that antagonizes T-cell-Tim-3-directed IO therapeutic efficacy. They further reveal MAPK targeting as a combination strategy for circumventing adverse consequences of unintended melanoma-Tim-3 inhibition.
Tim-3 is a growth-suppressive receptor intrinsic to melanoma cells, the blockade of which promotes MAPK-dependent tumorigenesis and thus counteracts antitumor activity of T-cell-directed Tim-3 inhibition.
T 细胞免疫球蛋白粘蛋白家族成员 3(Tim-3)是一种免疫检查点受体,可抑制效应功能并导致细胞毒性 T 细胞的终末耗竭。Tim-3 抑制剂正在免疫肿瘤学(IO)试验中进行研究,因为阻断 T 细胞-Tim-3 可增强抗肿瘤免疫力。在这里,我们确定了 Tim-3 作为内在的黑色素瘤细胞生长抑制受体的另一个作用。抑制黑色素瘤细胞-Tim-3 促进了免疫活性和免疫缺陷小鼠的肿瘤生长,而黑色素瘤特异性 Tim-3 过表达则减弱了肿瘤发生。Ab 介导的 Tim-3 阻断抑制了 T 细胞活性宿主中免疫原性鼠黑色素瘤的生长,与 T 细胞抑制的抗肿瘤作用一致。相比之下,Tim-3 Ab 给药刺激了 T 细胞缺陷小鼠中高免疫原性和低免疫原性鼠和人黑色素瘤的肿瘤发生,证实了黑色素瘤-Tim-3 拮抗的促肿瘤作用。黑色素瘤-Tim-3 的激活抑制了促有丝分裂的下游 MAPK 信号转导介质的磷酸化,而其阻断则增强了磷酸化。最后,药理 MAPK 抑制逆转了 T 细胞缺陷小鼠中不必要的 Tim-3 Ab 介导的肿瘤发生,并增强了 T 细胞活性宿主中 Tim-3 干扰的理想抗肿瘤活性。这些结果确定了黑色素瘤-Tim-3 阻断作为一种拮抗 T 细胞-Tim-3 导向 IO 治疗功效的机制。它们进一步揭示了 MAPK 靶向作为一种组合策略,可避免意外的黑色素瘤-Tim-3 抑制的不良后果。
Tim-3 是黑色素瘤细胞内在的生长抑制受体,其阻断可促进 MAPK 依赖性肿瘤发生,从而抵消了针对 T 细胞的 Tim-3 抑制的抗肿瘤活性。